|
1
|
Intensive versus conventional glucose control in critically ill patients.
|
N Engl J Med
|
2009
|
26.30
|
|
2
|
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
|
J Clin Oncol
|
2011
|
7.65
|
|
3
|
Hypoglycemia and risk of death in critically ill patients.
|
N Engl J Med
|
2012
|
6.17
|
|
4
|
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
|
J Clin Endocrinol Metab
|
2005
|
4.07
|
|
5
|
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas.
|
PLoS Genet
|
2005
|
2.85
|
|
6
|
Pheochromocytoma: current approaches and future directions.
|
Oncologist
|
2008
|
2.05
|
|
7
|
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
|
Clin Cancer Res
|
2005
|
1.95
|
|
8
|
Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types.
|
Am J Surg Pathol
|
2010
|
1.73
|
|
9
|
Bone as a source of FGF23: regulation by phosphate?
|
Bone
|
2004
|
1.63
|
|
10
|
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer.
|
Clin Cancer Res
|
2009
|
1.62
|
|
11
|
Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma.
|
J Clin Endocrinol Metab
|
2013
|
1.61
|
|
12
|
Potential pitfalls in the diagnosis of phaeochromocytoma.
|
Med J Aust
|
2005
|
1.61
|
|
13
|
Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
|
Hum Pathol
|
2010
|
1.56
|
|
14
|
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out.
|
Cancer Res
|
2009
|
1.53
|
|
15
|
Expanding indications for recombinant human TSH in thyroid cancer.
|
Thyroid
|
2008
|
1.49
|
|
16
|
Association of the TSHR gene with Graves' disease: the first disease specific locus.
|
Eur J Hum Genet
|
2005
|
1.49
|
|
17
|
Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas.
|
Clin Endocrinol (Oxf)
|
2013
|
1.46
|
|
18
|
Academic health science centres in Australia: let's get competitive.
|
Med J Aust
|
2011
|
1.43
|
|
19
|
BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.
|
Surgery
|
2010
|
1.36
|
|
20
|
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.
|
J Neuropathol Exp Neurol
|
2010
|
1.32
|
|
21
|
The role of Cdk5 in neuroendocrine thyroid cancer.
|
Cancer Cell
|
2013
|
1.30
|
|
22
|
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
|
J Neurooncol
|
2007
|
1.29
|
|
23
|
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
|
Clin Cancer Res
|
2006
|
1.27
|
|
24
|
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia.
|
J Clin Endocrinol Metab
|
2003
|
1.22
|
|
25
|
MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.
|
Clin Cancer Res
|
2011
|
1.22
|
|
26
|
Renal tumors associated with germline SDHB mutation show distinctive morphology.
|
Am J Surg Pathol
|
2011
|
1.21
|
|
27
|
Multikinase inhibitors: a new option for the treatment of thyroid cancer.
|
Nat Rev Endocrinol
|
2011
|
1.19
|
|
28
|
Phaeochromocytoma: current concepts.
|
Med J Aust
|
2005
|
1.18
|
|
29
|
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
|
Clin Endocrinol (Oxf)
|
2008
|
1.15
|
|
30
|
Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4.
|
N Engl J Med
|
2011
|
1.14
|
|
31
|
Comparative genomic hybridization analysis of adrenocortical tumors.
|
J Clin Endocrinol Metab
|
2002
|
1.12
|
|
32
|
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
|
Endocr Relat Cancer
|
2010
|
1.11
|
|
33
|
Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients.
|
Am J Surg Pathol
|
2014
|
1.11
|
|
34
|
Molecular markers and the pathogenesis of adrenocortical cancer.
|
Oncologist
|
2008
|
1.09
|
|
35
|
Elevated serum FGF23 concentrations in plasma cell dyscrasias.
|
Bone
|
2006
|
1.09
|
|
36
|
External ophthalmic findings in multiple endocrine neoplasia type 2B.
|
Clin Experiment Ophthalmol
|
2004
|
1.09
|
|
37
|
Wnt pathway inhibitors are strongly down-regulated in pituitary tumors.
|
Endocrinology
|
2007
|
1.07
|
|
38
|
IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients.
|
J Neuropathol Exp Neurol
|
2007
|
1.07
|
|
39
|
Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas.
|
J Clin Endocrinol Metab
|
2003
|
1.06
|
|
40
|
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
|
J Clin Endocrinol Metab
|
2013
|
1.05
|
|
41
|
MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers.
|
BMC Cancer
|
2014
|
1.05
|
|
42
|
MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
|
Cancer
|
2013
|
1.03
|
|
43
|
Vitamin D supplementation and bone mineral density in early postmenopausal women.
|
Am J Clin Nutr
|
2003
|
1.02
|
|
44
|
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma.
|
Endocr Relat Cancer
|
2008
|
1.00
|
|
45
|
Association of FOXE1 polyalanine repeat region with papillary thyroid cancer.
|
J Clin Endocrinol Metab
|
2012
|
1.00
|
|
46
|
Regulation of c-Ret in the developing kidney is responsive to Pax2 gene dosage.
|
Hum Mol Genet
|
2006
|
1.00
|
|
47
|
Genetic basis of phaeochromocytoma and paraganglioma.
|
Best Pract Res Clin Endocrinol Metab
|
2006
|
1.00
|
|
48
|
Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors.
|
Am J Surg Pathol
|
2013
|
0.99
|
|
49
|
Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma.
|
J Clin Endocrinol Metab
|
2003
|
0.98
|
|
50
|
Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes.
|
Ann N Y Acad Sci
|
2006
|
0.97
|
|
51
|
Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas.
|
J Clin Endocrinol Metab
|
2009
|
0.96
|
|
52
|
Surgery versus radioiodine therapy as definitive management for graves' disease: the role of patient preference.
|
Thyroid
|
2007
|
0.94
|
|
53
|
Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
|
Oncogene
|
2003
|
0.94
|
|
54
|
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
|
J Clin Endocrinol Metab
|
2008
|
0.94
|
|
55
|
Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype.
|
Cancer Res
|
2004
|
0.93
|
|
56
|
Clinical and molecular aspects of adrenocortical tumourigenesis.
|
ANZ J Surg
|
2003
|
0.92
|
|
57
|
The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
|
J Clin Endocrinol Metab
|
2005
|
0.92
|
|
58
|
PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth.
|
Endocrinology
|
2005
|
0.92
|
|
59
|
Current and emerging therapies for advanced adrenocortical carcinoma.
|
Oncologist
|
2011
|
0.92
|
|
60
|
K40E: a novel succinate dehydrogenase (SDH)B mutation causing familial phaeochromocytoma and paraganglioma.
|
Clin Endocrinol (Oxf)
|
2004
|
0.92
|
|
61
|
The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma.
|
Ann Surg Oncol
|
2009
|
0.91
|
|
62
|
Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors.
|
Ann Surg
|
2008
|
0.91
|
|
63
|
A case report in favor of a multistep adrenocortical tumorigenesis.
|
J Clin Endocrinol Metab
|
2003
|
0.90
|
|
64
|
Familial pituitary tumor syndromes.
|
Nat Rev Endocrinol
|
2009
|
0.90
|
|
65
|
Current management options for recurrent adrenocortical carcinoma.
|
Onco Targets Ther
|
2013
|
0.89
|
|
66
|
Predictive value of the Delphian and level VI nodes in papillary thyroid cancer.
|
ANZ J Surg
|
2010
|
0.88
|
|
67
|
CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
|
Endocr Relat Cancer
|
2010
|
0.88
|
|
68
|
Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline.
|
Thyroid
|
2006
|
0.88
|
|
69
|
Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma.
|
Nat Clin Pract Endocrinol Metab
|
2007
|
0.88
|
|
70
|
Noncoding RNA blockade of autophagy is therapeutic in medullary thyroid cancer.
|
Cancer Med
|
2014
|
0.87
|
|
71
|
Minimally invasive parathyroidectomy using the 'focused' lateral approach. I. Results of the first 100 consecutive cases.
|
ANZ J Surg
|
2002
|
0.87
|
|
72
|
Improving Outcomes in Adrenocortical Cancer: An Australian Perspective.
|
Ann Surg Oncol
|
2014
|
0.85
|
|
73
|
A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.
|
Am J Surg Pathol
|
2015
|
0.83
|
|
74
|
Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
|
Ann Surg Oncol
|
2010
|
0.82
|
|
75
|
Succinate dehydrogenase deficiency is rare in pituitary adenomas.
|
Am J Surg Pathol
|
2014
|
0.82
|
|
76
|
Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
|
Clin Endocrinol (Oxf)
|
2005
|
0.82
|
|
77
|
The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors.
|
J Clin Endocrinol Metab
|
2009
|
0.82
|
|
78
|
5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.
|
Int J Colorectal Dis
|
2006
|
0.81
|
|
79
|
Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma.
|
Cancer Gene Ther
|
2004
|
0.81
|
|
80
|
A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones.
|
J Pediatr
|
2004
|
0.80
|
|
81
|
Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism.
|
Am J Pathol
|
2002
|
0.80
|
|
82
|
Progenitor cell line (hPheo1) derived from a human pheochromocytoma tumor.
|
PLoS One
|
2013
|
0.80
|
|
83
|
Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma.
|
J Surg Res
|
2008
|
0.80
|
|
84
|
Impact of month of birth on the development of autoimmune thyroid disease in the United Kingdom and Europe.
|
J Clin Endocrinol Metab
|
2014
|
0.79
|
|
85
|
Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma.
|
Mol Cancer Ther
|
2008
|
0.79
|
|
86
|
Evolution of the "autophagamiR".
|
Autophagy
|
2011
|
0.79
|
|
87
|
A commonly occurring polymorphism upstream of the estrogen receptor alpha alters transcription and is associated with increased HDL.
|
Atherosclerosis
|
2008
|
0.79
|
|
88
|
Nodal metastasis microRNA expression correlates with the primary tumour in MTC.
|
ANZ J Surg
|
2012
|
0.78
|
|
89
|
New era: prophylactic surgery for patients with multiple endocrine neoplasia-2a.
|
ANZ J Surg
|
2006
|
0.78
|
|
90
|
NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.
|
Am J Surg Pathol
|
2017
|
0.78
|
|
91
|
Mucoepidermoid carcinoma of the thyroid: a report of three cases and postulated histogenesis.
|
Thyroid
|
2012
|
0.77
|
|
92
|
Oncophagy: harnessing regulation of autophagy in cancer therapy.
|
Endocr Relat Cancer
|
2012
|
0.77
|
|
93
|
Intra-abdominal insular thyroid carcinoma metastasis.
|
Thyroid
|
2009
|
0.77
|
|
94
|
Increase in presentations and procedure rates for hyperparathyroidism in Northern Sydney and New South Wales.
|
Med J Aust
|
2002
|
0.77
|
|
95
|
Restoring TGFbeta function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation.
|
Int J Colorectal Dis
|
2008
|
0.77
|
|
96
|
Nonfunctioning parathyroid cancer presenting as a cervical mass.
|
Thyroid
|
2008
|
0.77
|
|
97
|
Outcomes of minimally invasive surgery for phaeochromocytoma.
|
ANZ J Surg
|
2009
|
0.77
|
|
98
|
Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway.
|
Gene
|
2002
|
0.76
|
|
99
|
Routine screening for germline RET mutations is recommended for all patients with medullary thyroid cancer.
|
Nat Clin Pract Endocrinol Metab
|
2008
|
0.75
|
|
100
|
Pituitary metastasis from breast cancer presenting as diabetes insipidus.
|
BMJ Case Rep
|
2014
|
0.75
|
|
101
|
Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism.
|
J Mol Diagn
|
2006
|
0.75
|
|
102
|
Responses to access block in Australia: Royal North Shore Hospital.
|
Med J Aust
|
2003
|
0.75
|
|
103
|
Paediatric bilateral adrenal phaeochromocytomas in association with a novel mutation in the von Hippel Lindau gene.
|
J Paediatr Child Health
|
2008
|
0.75
|
|
104
|
Bioactivity of PTH/PTHrP analogs lacking the 1-14 N-terminal domain.
|
Mol Cell Endocrinol
|
2002
|
0.75
|
|
105
|
Medullary thyroid carcinoma presenting with an initial CEA elevation.
|
ANZ J Surg
|
2010
|
0.75
|
|
106
|
Timing of iodine-123 scintigraphy following use of recombinant human thyrotropin in differentiated thyroid carcinoma.
|
Clin Nucl Med
|
2007
|
0.75
|
|
107
|
Do all patients with RET mutations associated with multiple endocrine neoplasia type 2 require surgery?
|
Nat Clin Pract Endocrinol Metab
|
2005
|
0.75
|
|
108
|
Calcitonin-specific transcription and splicing targets gene-directed enzyme prodrug therapy to medullary thyroid carcinoma cells.
|
J Clin Endocrinol Metab
|
2003
|
0.75
|
|
109
|
Pheochromocytoma-quo vadis?
|
Nat Clin Pract Endocrinol Metab
|
2007
|
0.75
|
|
110
|
Does genetic screening increase detection of familial medullary thyroid cancer in apparently sporadic cases?
|
Nat Clin Pract Endocrinol Metab
|
2007
|
0.75
|
|
111
|
Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma.
|
J Clin Neurosci
|
2010
|
0.75
|
|
112
|
Papillary thyroid carcinoma in pregnancy: a variant of the disease?
|
Ann Surg Oncol
|
2012
|
0.75
|